Journal article
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
Abstract
PurposeIn the KATHERINE study (NCT01772472), patients with HER2-positive early breast cancer (EBC) and residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy who were treated with adjuvant trastuzumab emtansine (T-DM1) had a 50% reduction in the risk of an invasive disease-free survival (IDFS) event compared to patients treated with adjuvant trastuzumab. In metastatic disease, T-DM1 has resulted in higher rates of …
Authors
Huang C-S; Yang Y; Kwong A; Chen S-C; Tseng L-M; Liu M-C; Shen K; Wang S; Ng T-Y; Feng Y
Journal
Breast Cancer Research and Treatment, Vol. 187, No. 3, pp. 759–768
Publisher
Springer Nature
Publication Date
6 2021
DOI
10.1007/s10549-021-06166-y
ISSN
0167-6806